Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?
Tumor draining sentinel lymph nodes (SLNs) are the sites of selective changes as compared to non-SLNs. They show features of tumor-reactive lymphadenopathy, including increased total number of functional blood vessels, but a relative immunosuppressed status has also been described in them. We explored the hypothesis of a selective regression or non-regression in SLNs versus non-SLNs in 142 patients with 110 estrogen receptor-positive and 32 estrogen receptor-negative tumors undergoing both SLN biopsy and axillary lymph node dissection after neoadjuvant therapy by assessing the tumoral (metastatic) and regression statuses of SLNs and non-SLNs separately. Of the 89 cases with signs of nodal regression, 22 cases (25%) were in favor of a selective non-regression in SLNs, 18 cases (20%) were supportive of a selective and more pronounced regression in the SLNs and the remaining showed equal degrees of regression or non-regression in SLNs and non-SLNs. The results indicate that there is no obvious difference in the degree of regressive histological changes shown by SLNs and NSLNs. Therefore, this phenomenon may not be a major contributor to the higher false negative rate of SLN biopsy after neoadjuvant treatment.
KeywordsSentinel lymph node Non-sentinel lymph node Breast cancer Neoadjuvant therapy Selective regression
The study was supported by the National Research, Development and Innovation Office grant GINOP-2.3.2-15-2016-00020. The content of the communications has not been influenced by this support.
- 3.Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Ditlev J, Tsarfaty I, Hudson E, Jackson DG, Petillo D, Chen J, Resau JH, Teh BT (2006) Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res 66:10365–10376CrossRefPubMedGoogle Scholar
- 8.Wells CA, Amendoeira I, Bellocq JP et al (2012) S2: pathology update. Quality assurance guidelines for pathology. In: Perry N, Broeders M, de Wolf C et al (eds) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn, supplements. European Commission, Office for Official Publications of the European Union, Luxembourg, pp 73–120Google Scholar